Entyvio

Pharma

Takeda's Entyvio keeps its strong IBD position despite threats

With a new subcutaneous formulation for Entyvio, the company isn't worried about new entrants affecting its leading spot in the first-line IBD market.

Zoey Becker Jul 31, 2024 4:43pm

The top 10 pharma drug ad spenders for 2023

Jun 3, 2024 3:00am

Takeda plots $900M restructuring plan as profits plummet

May 9, 2024 12:00pm

Takeda treads water despite loss of exclusivity on Vyvanse

Feb 1, 2024 1:56pm

FDA signs off on Takeda's subcutaneous version of Entyvio

Sep 28, 2023 11:32am

Takeda expects patent expirations to weigh on earnings

May 12, 2023 11:10am